ReviewClinical, cosmetic and investigational dermatology2026
Literature Review: Recent Therapeutic Advances in The Management of Prurigo Nodularis: From Conventional Therapy to Biologics and Targeted Small-Molecule Agents.
Review in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prurigo nodularis (PN) is a chronic inflammatory disease characterized by hyperkeratotic nodules on extensor surfaces, perpetuating a vicious itch-scratch cycle. Its epidemiologic burden is substantial, and diagnosis remains primarily clinical, supported by a structured diagnostic algorithm and evaluation for associated comorbidities. PN pathogenesis involves interactions among keratinocytes, immune cells, sensory nerve fibers and neuropeptides (substance P and calcitonin gene-related peptide) that elicit intense pruritus. Therapy aims to break the itch-scratch cycle and accelerate lesion resolution by reducing pruritus. Standard management with topical agents (corticosteroids, calcineurin inhibitors), systemic therapies (antihistamines, methotrexate, cyclosporine) and phototherapy often yields incomplete responses and requires prolonged treatment. Consequently, targeted therapies are critical to optimizing clinical efficacy. Dupilumab is currently the first Food and Drug Administration (FDA)-approved biologic for PN, followed by nemolizumab whereas other emerging agents-including additional monoclonal antibodies, Janus kinase (JAK) inhibitors, neurokinin-1 (NK1) receptor antagonists, opioid antagonists, and neuromodulators-remain at varying stages of clinical investigation (Phase II-III), acting on cytokine-neuroinflammatory pathways to relieve pruritus and improve patients' quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.